Article: Sinovac Biotech Ltd.: Update on Human Clinical Trials of SARS Vaccine; Additional 14 Volunteers Healthy After First Inoculation.

BEIJING -- Sinovac Biotech Ltd. ("Sinovac") (OTCBB:SNVBF) announced that the second subgroup of 14 volunteers in Phase 1 clinical trials of its SARS vaccine received their first inoculation two weeks ago and results of recent blood testing has shown that there are no adverse reactions reported to date. The inoculation process of the initial 4 volunteers as first reported on May 25th, 2004 has been completed. Those first 4 volunteers received their initial inoculation on May 22, 2004, and after no adverse side effects were observed, the volunteers received a second inoculation on 19 June 2004. Upon completion of the first 30-day observation period those recipients remain ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!